Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2064-2077

  Shi, Hao ^a   Verma, Mayank ^a   Zhang, Lei ^a   Dong, Chen ^b   Flavell, Richard A ^a   Bennett, Anton M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MKP5 PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DELETION; IMMUNOHISTOCHEMISTRY; MOUSE; MUSCLE CELL; MUSCLE DEVELOPMENT; MUSCLE REGENERATION; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NEGATIVE FEEDBACK; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL;

ANIMALS; CELL PROLIFERATION; CROSSES, GENETIC; DUAL-SPECIFICITY PHOSPHATASES; DYSTROPHIN; FEMALE; MALE; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; MUSCLES; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REGENERATION; STEM CELLS;

EID: 84877135603     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64375     Document Type: Article

References (59)

1. Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol. 2001;91(2):534-551.
2. Seale P, Rudnicki MA. A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev Biol. 2000;218(2):115-124.
3. Wagers AJ, Conboy IM. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell. 2005;122(5):659-667.
4. Shi X, Garry DJ. Muscle stem cells in development, regeneration, and disease. Genes Dev. 2006; 20(13):1692-1708.
5. Buckingham M, Montarras D. Skeletal muscle stem cells. Curr Opin Genet Dev. 2008;18(4):330-336.
6. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell. 2007;129(5):999-1010.
7. Bischoff R. Chemotaxis of skeletal muscle satellite cells. Dev Dyn. 1997;208(4):505-517.
8. Rudnicki MA, Le Grand F, McKinnell I, Kuang S. The molecular regulation of muscle stem cell function. Cold Spring Harb Symp Quant Biol. 2008; 73:323-331.
9. Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010;120(1):11-19.
10. Montarras D, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science. 2005; 309(5743):2064-2067.
11. Nishino I, Ozawa E. Muscular dystrophies. Curr Opin Neurol. 2002;15(5):539-544.
12. Porter JD. Introduction to muscular dystrophy. Microsc Res Tech. 2000;48(3-4):127-130.
13. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928.
14. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993;90(8):3710-3714.
15. Bhatnagar S, Kumar A. Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med (Berl). 2010;88(2):155-166.
16. Blau HM, Webster C, Pavlath GK. Defective myoblasts identified in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A. 1983;80(15):4856-4860.
17. Sacco A, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell. 2010;143(7):1059-1071.
18. Cuenda A, Cohen P. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem. 1999; 274(7):4341-4346.
19. Weston AD, Sampaio AV, Ridgeway AG, Underhill TM. Inhibition of p38 MAPK signaling promotes late stages of myogenesis. J Cell Sci. 2003; 116(pt 14):2885-2893.
20. Kondoh K, Sunadome K, Nishida E. Notch signaling suppresses p38 MAPK activity via induction of MKP-1 in myogenesis. J Biol Chem. 2007; 282(5):3058-3065.
21. Perdiguero E, et al. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation. EMBO J. 2007;26(5):1245-1256.
22. Lluis F, Perdiguero E, Nebreda AR, Munoz-Canoves P. Regulation of skeletal muscle gene expression by p38 MAP kinases. Trends Cell Biol. 2006;16(1):36-44.
23. Keren A, Tamir Y, Bengal E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol Cell Endocrinol. 2006;252(1-2):224-230.
24. Jones NC, et al. The p38alpha/beta MAPK functions as a molecular switch to activate the quiescent satellite cell. J Cell Biol. 2005;169(1):105-116.
25. Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, Bengal E. Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J Biol Chem. 1998;273(17):10436-10444.
26. Milasincic DJ, Calera MR, Farmer SR, Pilch PF. Stimulation of C2C12 myoblast growth by basic fibroblast growth factor and insulin-like growth factor 1 can occur via mitogen-activated protein kinase-dependent and -independent pathways. Mol Cell Biol. 1996;16(11):5964-5973.
27. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem. 1997;272(10):6653-6662.
28. Weyman CM, Ramocki MB, Taparowsky EJ, Wolfman A. Distinct signaling pathways regulate transformation and inhibition of skeletal muscle differentiation by oncogenic Ras. Oncogene. 1997; 14(6):697-704.
29. Jones NC, Fedorov YV, Rosenthal RS, Olwin BB. ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. J Cell Physiol. 2001;186(1):104-115.
30. Gallo R, Serafini M, Castellani L, Falcone G, Alem S. Distinct effects of Rac1 on differentiation of primary avian myoblasts. Mol Biol Cell. 1999; 10(10):3137-3150.
31. Meriane M, Charrasse S, Comunale F, Gauthier-Rouviere C. Transforming growth factor beta activates Rac1 and Cdc42Hs GTPases and the JNK pathway in skeletal muscle cells. Biol Cell. 2002;94(7-8):535-543.
32. Khurana A, Dey CS. Involvement of c-Jun N-terminal kinase activities in skeletal muscle differentiation. J Muscle Res Cell Motil. 2004;25(8):645-655.
33. Dickinson RJ, Keyse SM. Diverse physiological functions for dual-specificity MAP kinase phos-phatases. J Cell Sci. 2006;119(pt 22):4607-4615.
34. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 2007;26(22):3203-3213.
35. Boutros T, Chevet E, Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phos-phatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev. 2008;60(3):261-310.
36. Lawan A, Shi H, Gatzke F, Bennett AM. Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cell Mol Life Sci. 2013; 70(2):223-237.
37. Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mito-gen-activated protein kinases. Science. 1997; 278(5341):1288-1291.
38. Roth RJ, et al. MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in mice. J Clin Invest. 2009;119(12):3817- 3829.
39. Shi H, et al. Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling. FASEB J. 2008;22(8):2990-3000.
40. Shi H, et al. Mitogen-activated protein kinase signaling is necessary for the maintenance of skeletal muscle mass. Am J Physiol Cell Physiol. 2009; 296(5):C1040-C1048.
41. Shi H, Zeng C, Ricome A, Hannon KM, Grant AL, Gerrard DE. Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. Am J Physiol Cell Physiol. 2007;292(5):C1681-C1689.
42. Wu JJ, et al. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metabolism. 2006;4(1):61-73.
43. Shi H, et al. MAP kinase phosphatase-1 deficiency impairs skeletal muscle regeneration and exacerbates muscular dystrophy. FASEB J. 2010;24(8):2985-2997.
44. Zhang Y, et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature. 2004;430(7001):793-797.
45. Qian F, et al. A non-redundant role for MKP5 in limiting ROS production and preventing LPS-induced vascular injury. EMBO J. 2009;28(19):2896-2907.
46. Theodosiou A, Smith A, Gillieron C, Arkinstall S, Ashworth A. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 1999;18(50):6981-6988.
47. Masuda K, Shima H, Kikuchi K, Watanabe Y, Mat-suda Y. Expression and comparative chromosomal mapping of MKP-5 genes DUSP10/Dusp10. Cytogenet Cell Genet. 2000;90(1-2):71-74.
48. Stedman HH, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991; 352(6335):536-539.
49. Suelves M, et al. uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol. 2007; 178(6):1039-1051.
50. Shea KL, et al. Sprouty1 regulates reversible quiescence of a self-renewing adult muscle stem cell pool during regeneration. Cell Stem Cell. 2010; 6(2):117-129.
51. Cenciarelli C, et al. Critical role played by cyclin D3 in the MyoD-mediated arrest of cell cycle during myoblast differentiation. Mol Cell Biol. 1999; 19(7):5203-5217.
52. Kiess M, Gill RM, Hamel PA. Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene. 1995;10(1):159-166.
53. De Santa F, Albini S, Mezzaroma E, Baron L, Felsani A, Caruso M. pRb-dependent cyclin D3 protein stabilization is required for myogenic differentiation. Mol Cell Biol. 2007;27(20):7248-7265.
54. Szelenyi ER, Urso ML. Time-course analysis of injured skeletal muscle suggests a critical involvement of ERK1/2 signaling in the acute inflammatory response. Muscle Nerve. 2012;45(4):552-561.
55. Alter J, Rozentzweig D, Bengal E. Inhibition of myoblast differentiation by tumor necrosis factor alpha is mediated by c-Jun N-terminal kinase 1 and leukemia inhibitory factor. J Biol Chem. 2008; 283(34):23224-23234.
56. Wang H, Xu Q, Xiao F, Jiang Y, Wu Z. Involvement of the p38 mitogen-activated protein kinase alpha, beta, and gamma isoforms in myogenic differentiation. Mol Biol Cell. 2008;19(4):1519-1528.
57. Rao SS, Kohtz DS. Positive and negative regulation of D-type cyclin expression in skeletal myoblasts by basic fibroblast growth factor and transforming growth factor β. J Biol Chem. 1995;270(8):4093-4100.
58. Tanoue T, Moriguchi T, Nishida E. Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J Biol Chem. 1999; 274(28):19949-19956.
59. Wu JJ, Zhang L, Bennett AM. The noncatalytic amino terminus of mitogen-activated protein kinase phosphatase 1 directs nuclear targeting and serum response element transcriptional regulation. Mol Cell Biol. 2005;25(11):4792-4803.